Relay Therapeutics, Inc.
RLAYDrugs in Pipeline
1
Phase 3 Programs
1
Upcoming Catalysts
1
Next Catalyst
Aug 6, 2026
3dMarket Overview
Stock performance and key metrics
1 upcoming, 0 past
RLAY Earnings Report
EPS Est: $-0.41 | FQ end 2026-06
How RLAY's past catalysts played out
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
RLY-2608 | Phase 3 | PIK3CA Mutation | - | - |
PIK3CA Mutation
1 drug in this indication
PIK3CA-Related Overgrowth Spectrum (PROS)
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Relay Therapeutics, Inc.'s drug pipeline?→
CatalystAlert tracks 1 drug candidate in Relay Therapeutics, Inc.'s (RLAY) pipeline across Phase 3. Its lead program is RLY-2608 (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Relay Therapeutics, Inc.'s next FDA catalyst?→
Relay Therapeutics, Inc.'s (RLAY) next tracked catalyst is a Earnings expected August 6, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track RLAY biotech catalysts?→
Add RLAY to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Relay Therapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.